Scarica l'app Stockscreener
5.54
0.18%
0.010
Dopo l'orario di chiusura:
5.48
-0.06
-1.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - ChartMill
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
Why did MNKD stock jump over 7% in pre-market today? - MSN
MannKind’s Afrezza Pediatric Review Sparks Questions On Undervaluation And Risk - Yahoo Finance
How Afrezza’s Pediatric Trial and FDA Review Could Reshape MannKind’s (MNKD) Risk‑Reward Profile - Yahoo Finance
Assessing MannKind (MNKD) Valuation After Afrezza Pediatric Expansion Progress And New Growth Initiatives - Yahoo Finance
(02/13/26) Top Picks 2026: MannKind Corp. (MNKD) - moneyshow.com
Top Picks 2026- MannKind Corp. MNKD - Yahoo Finance
MannKind (NASDAQ:MNKD) Shares Cross Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Can MannKind Corporation stock double in the next yearLong Setup & AI Powered Market Entry Strategies - mfd.ru
MannKind (MNKD) Begins Enrollment for Pediatric Diabetes Study - GuruFocus
MannKind enrolls first patient in pediatric inhaled insulin study - Investing.com
Inhaled insulin trial aims to cut shots for kids with new type 1 diabetes - Stock Titan
MannKind Corp Is Suddenly Everywhere – But Is MNKD Actually Worth Your Money? - AD HOC NEWS
Fund Flows: Whats the beta of MannKind Corporation stockWeekly Gains Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Benzinga
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Investing News Network
Analysts Offer Insights on Healthcare Companies: Humana (HUM), MannKind (MNKD) and Inspire Medical Systems (INSP) - The Globe and Mail
MannKind stock gets Buy rating reaffirmation from Truist at $9 target - Investing.com
FDA approves updated dosing guidelines for MannKind’s inhaled insulin By Investing.com - Investing.com Canada
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - Cantech Letter
Avant Technologies Leads Transformation in Healthcare Market - Intellectia AI
MannKind (NASDAQ:MNKD) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates 'Buy' Rating for MNKD with $11 Ta - GuruFocus
MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - Finviz
MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza - Stocktwits
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? - Asianet Newsable
MannKind stock rises after FDA approves updated Afrezza label By Investing.com - Investing.com Canada
MannKind stock rises after FDA approves updated Afrezza label - Investing.com
FDA approves updated dosing guidelines for MannKind’s inhaled insulin - Investing.com
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - ChartMill
MannKind’s Volatile Week: Can MNKD Justify The Recent Rebound In Its Stock? - AD HOC NEWS
Growth Report: What hedge funds are buying MannKind CorporationJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Investment Recap: Is MannKind Corporation backed by strong institutional buying - baoquankhu1.vn
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative - Yahoo Finance
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Short Interest in MannKind Corporation (NASDAQ:MNKD) Grows By 26.1% - MarketBeat
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers - Insider Monkey
MannKind (NASDAQ:MNKD) Shares Down 6.4%Here's What Happened - MarketBeat
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile - Yahoo Finance
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
MannKind (NASDAQ:MNKD) Raised to Strong-Buy at Zacks Research - MarketBeat
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deltec Asset Management LLC Takes $3.89 Million Position in MannKind Corporation $MNKD - MarketBeat
Mannkind’s chief people officer sells $297k in stock By Investing.com - Investing.com Nigeria
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Stuart Tross Sells 47,006 Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind’s chief people officer sells $297k in stock - Investing.com
MannKind Corp stock hits 52-week high at 6.33 USD By Investing.com - Investing.com Nigeria
Pharma news weekly roundup - The Pharma Letter
Is MannKind Corporation stock affected by interest rate hikesMarket Trend Review & Consistent Profit Alerts - ulpravda.ru
How MannKind Corporation stock reacts to Fed rate cutsJuly 2025 Snapshot & Safe Swing Trade Setups - ulpravda.ru
0.34%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):